R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma.

被引：0
|
作者：
Freyer, Craig [1 ]
George, Timothy [1 ]
Price, Samantha [1 ]
Shah, Bijal Dinesh [1 ]
Bello, Celeste M. [1 ]
Sokol, Lubomir [1 ]
Sotomayor, Eduardo M. [1 ]
Cultrera, Jennifer L. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18509
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma
    Pienkowska-Grela, B
    Witkowska, A
    Grygalewicz, B
    Rymkiewicz, G
    Rygier, J
    Woroniecka, R
    Walewski, J
    CANCER GENETICS AND CYTOGENETICS, 2005, 156 (02) : 114 - 121
  • [32] Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma
    Softic, Adaleta
    Begic, Leila
    Halilbasic, Alma
    Kos, Janko
    MEDICINSKI GLASNIK, 2011, 8 (01) : 97 - 100
  • [33] Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma
    Demetriou, Nicholas
    Burkart, Madelyn
    Sunderraj, Ashwin
    Ma, Shuo
    Winter, Jane N.
    Gordon, Leo I.
    Karmali, Reem
    Roy, Ishan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma
    Moleti, Maria L.
    Testi, Anna M.
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : 826 - 843
  • [35] Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Khurana, Arushi
    Al Saleh, Abdullah S.
    Gandhi, Sangeetha
    Truong, Tuan A.
    Bennani, Nabila
    Paludo, Jonas
    Villasboas, Jose C.
    Johnston, Patrick B.
    Ansell, Stephen M.
    Lin, Yi
    BLOOD, 2020, 136
  • [36] Selinexor in Combination with R-GDP/R-ICE Regimen for Refractory Aggressive Large B-Cell Lymphoma Patients with TP53 Alterations
    Wang, Li
    Liu, Mengke
    Fang, Ying
    Zhang, Muchen
    Xiong, Jie
    Cheng, Lili
    Zhao, Weili
    BLOOD, 2022, 140 : 9542 - 9543
  • [37] Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Witzig, Thomas E.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 655 - 668
  • [38] ESHAP with rituximab is highly efficacious with durable responses in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Threja, RR
    Venugopal, P
    Gregory, SA
    O'Brien, T
    Bogdanova, E
    BLOOD, 2005, 106 (11) : 277B - 277B
  • [39] Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Venugopal, P
    Gretory, SA
    Showel, J
    Shammo, J
    Enschede, S
    Larson, M
    Obrien, T
    Sokolovsky, TD
    Means, A
    BLOOD, 2004, 104 (11) : 243B - 243B
  • [40] A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
    Rutherford, Sarah C.
    Allan, John N.
    Ruan, Jia
    Furman, Richard R.
    Richards, Kristy
    Rodriguez, Amelyn
    Gololobova, Kseniya
    Garcia, Arcania
    Cerchietti, Leandro
    Marullo, Rossella
    Chen, Zhengming
    Santamala, Jennifer
    Shore, Tsiporah B.
    Phillips, Adrienne A.
    Mayer, Sebastian
    Hsu, Jingmei
    Gergis, Usama
    Senese, Silvia
    Ali-Shaw, Trisha
    Rahim, Riyaad
    van Besien, Koen
    Leonard, John P.
    Martin, Peter
    BLOOD, 2020, 136
12345